Physician profile
Gary C Burke
NPI 1598744898
$3,899.16
in general payments reported to CMS, 2019-2025
22 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $276 · 2021: $502 · 2022: $780 · 2023: $570 · 2024: $811 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $906.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $553.35 | 2020-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $413.77 | 2021-2025 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $392.00 | 2019-2024 | Lifevest |
| W. L. Gore & Associates, INC. | $222.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $220.44 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.40 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $178.75 | 2024-2025 | Optimizer |
| Amgen INC. | $169.64 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $152.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $84.59 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $79.26 | 2019-2022 | |
| Scpharmaceuticals INC. | $64.31 | 2023-2024 | |
| American Regent | $50.97 | 2025 | Injectafer |
| Edwards Lifesciences Corporation | $49.42 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45.30 | 2019-2025 | Wegovy |
| Irhythm Technologies, INC. | $37.11 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $26.38 | 2019-2024 | Evkeeza |
| Preventice Services, LLC | $25.78 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $15.34 | 2024 | Arcalyst |
| Astellas Pharma US INC | $14.14 | 2019 | |
| Esperion Therapeutics, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.